NEW YORK (GenomeWeb) – Astute Medical said this week that it has entered a strategic collaboration with Ortho-Clinical Diagnostics to expand sales of its NephroCheck test for acute kidney injury.
Under the agreement, in exchange for a $15 million equity investment from OCD, Astute has made the company the exclusive sales agent for NephroCheck and the Astute 140 Meter device on which the test is performed in portions of the EU and, upon regulatory approval, in the US.
Astute has also granted OCD a semi-exclusive global license to develop and commercialize a version of NephroCheck for use on OCD's Vitros line of automated testing platforms.